Semi-Annual Report — FY2026 H1
What KOBAYASHI PHARMACEUTICAL CO.,LTD. reported for the period from 2026-01-01 to 2026-12-31.
Filed 2026-08-07View the original on EDINET
How much it says
64Detailed
What moved here
14named for the first time
Its own wording
29terms
Which filing this is
35/ 35newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the interim consolidated accounting period, revenue increased year on year despite the effects of geopolitical conditions, logistics, materials and foreign exchange related to heightened tensions in the Middle East, while operating income, ordinary income and interim net income attributable to owners of the parent all declined. In addition to recording losses related to the recall of beni-koji-related products and beginning operations at the new domestic research facility, the Sai-to Manufacturing Lab, the Company completed the sale of investment securities and resolved to transfer its interest in a Chinese subsidiary.
Komori's summary of this document, not the document's own words.64Detailed
How much this filing saysA weighted roll-up of 12 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 35 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
93
Very detailed
68
Detailed
70
Detailed
62
Detailed
0
Almost nothing
50
Typical
68
Detailed
100
Very detailed
100
Very detailed
53
Typical
0
Almost nothing
73
Detailed
R&D spend40億円Money spent making new things.
Cash left over40億円Cash from the business, less what went into equipment.
Spent on equipment176億円Plants, machines — things meant to last.
EmployeesNot disclosedThis document does not carry the figure.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.